Sabby Management’s Aldeyra Therapeutics ALDX Stock Holding History

Sabby Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-427	Closed	-$589K	–	124
2018 Q3	$589K	Buy	+427	New	+$3.46K	0.08%	70

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Sabby Management's ALDX Position: Q3 2017 in Review

Sabby Management sold out of Aldeyra Therapeutics (ALDX) in Q3 2017, closing a stake of 97,704 shares — an estimated $454K sold.

Sabby Management first reported a position in ALDX in Q2 2015 and held it in 6 quarters. The position peaked at $2.07M in Q2 2015. 35 funds tracked by Wall St. Rank hold ALDX as of Q3 2017.

Sabby Management reported no remaining Aldeyra Therapeutics position as of Q3 2017 after selling out during the quarter.
Sabby Management sold 97,704 Aldeyra Therapeutics shares in Q3 2017, an estimated $454K.
Sabby Management first reported a position in Aldeyra Therapeutics in Q2 2015 and held it in 6 quarters.
Sabby Management's Aldeyra Therapeutics position peaked at $2.07M in Q2 2015.
35 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.